lenalidomide - Generic mfg.
Lunsumio (mosunetuzumab) - Roche, Biogen
Lunsumio + lenalidomide: Interim analysis data from P3 Celestimo trial (NCT04712097) for 2L+ follicular lymphoma in 2024 (Roche) - Jul 27, 2023 - H1 2023 Results 
P3 data • Follicular Lymphoma • Hematological Malignancies • Oncology
https://assets.roche.com/f/176343/x/418a8c95c6/irp230727.pdf
 
Jul 27, 2023
 
 
91f1782f-8ba5-4f38-a739-0958192712f3.png